touchONCOLOGY caught up with Professor Angela Lamarca (Christie NHS Foundation Trust, Manchester, UK) to discuss her highlights from the Liver Cancer Summit 2022, targeted therapies for cholangiocarcinoma and some of the most important current trial data in hepatic-biliary oncology (the HIMALAYA and TOPAZ-1 studies).
- What were your highlights and hot topics from the Liver Cancer Summit 2022? 00:20-00:58
- How are targeted therapies changing the treatment paradigm for cholangiocarcinoma? 00:58-02:07
- Could you tell us a little about the HIMALAYA study? 02:07-02:48
- How will the results from the phase III TOPAZ-1 trial impact clinical practice for patients with advanced cholangiocarcinoma? 02:48-03:17
- What do you consider the main unmet educational needs in hepatic-biliary oncology? 03:17-04:04
Speaker Disclosure: Angela Lamarca has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the Liver Cancer Summit 2022
Share this Video
Related Videos In Gastrointestinal Oncology
Angela Lamarca, ESMO 2022: ABC-06 trial, quality of life results – Symptom-control with FOLFOX in the treatment of advanced biliary cancers
The ABC-06 clinical trial established active-symptom control + oxaliplatin/5-FU chemotherapy (FOLFOX) as the standard of care treatment after Cisplatin and Gemcitabine for advanced biliary cancers. Dr Angela Lamarca (Fundación Jiménez Diaz University Hospital, Madrid, Spain) joins touchONCOLOGY to discuss the efficacy and safety of second-line active- symptom-control with FOLFOX, and the quality of life and […]
Alvaro Arjona-Sanchez, ESMO 2022: HIPECT4 phase 3 trial investigating the efficacy and safety of adjuvant HIPEC in patients with locally advanced colon cancer
Peritoneal metastasis in locally advanced colon cancer has a poor prognosis from 3 years post surgical resection. Dr Alvaro Arjona-Sanchez (Institute of Biomedical Research IMIBIC, University Hospital Reina Sofia, Cordoba, Spain) joins touchONCOLOGY to discuss the HIPECT4 phase 3 trial investigating the efficacy and safety of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with locally […]
Myriam Chalabi, ESMO 2022: Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: the NICHE-2 study
Neoadjuvant immunotherapy has shown promising responses in several cancer types. In this touchONCOLOGY interview Dr Myriam Chalabi (Netherlands Cancer Institute, Amsterdam, Netherlands) discusses the NICHE-2 study results, investigating patients with non-metastatic deficient DNA mismatch repair (dMMR) colon cancer, treated with one dose of ipilimumab and two doses of nivolumab and underwent surgery ≤6 weeks of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!